Bevacizumab in the treatment of metastatic colorectal cancer: the RFOM in the experience of the A.O. University of Siena Authors Davide Paoletti Azienda Ospedaliera Universitaria Senese, Settore Governo Clinico della Spesa Farmaceutica, Siena - Italy Silvano Giorgi Azienda Ospedaliera Universitaria Senese, Settore Governo Clinico della Spesa Farmaceutica, Siena - Italy DOI: https://doi.org/10.33393/grhta.2015.326
Downloads PDF (Italian) Issue Vol. 2 No. 1 (2015): January-April 2015 Section Correspondence License Copyright (c) 2015 The authors This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. How to Cite Bevacizumab in the treatment of metastatic colorectal cancer: the RFOM in the experience of the A.O. University of Siena. (2015). Global and Regional Health Technology Assessment, 2(1), 61-62. https://doi.org/10.33393/grhta.2015.326 More Citation Formats ABNT ACM ACS APA Chicago Harvard IEEE MLA Turabian Vancouver Download Citation Endnote/Zotero/Mendeley (RIS) BibTeX Received 2019-11-07 Published 2015-03-17 Statistics Abstract: 756 PDF: 540 Sign up Browse Sections Health Technology Assessment Health Policies banners150 Completed peer reviews since:November 4, 2020 Real-world application of an integrated MCDA–economic framework in continence care technology: a hospital-based case study 240 Budget impact of MhZT for intermittent catheterization in people with multiple sclerosis or spinal cord injury in Italy 232 More and earlier data from AIFA: do they impact on the regional policies? Results from an exploratory analysis 195 The AIFA reform and evaluation timelines for new drugs: the impact of the Scientific and Economic Commission 193 Health technology assessment of an automated unitdose drug distribution system in a high-specialization national referral hospital of the Italian National Health Service 184